{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:58Z","timestamp":1761864238045,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011781","name":"Shriners Hospitals for Children Boston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.bone.2021.115867","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:30:55Z","timestamp":1611894655000},"page":"115867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta"],"prefix":"10.1016","volume":"145","author":[{"given":"Iris","family":"Boraschi-Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Polak-Nachumow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.115867_bb0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115867_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis imperfecta: new perspectives from clinical and translational research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2021.115867_bb0015","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bone.2021.115867_bb0020","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","article-title":"DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum","volume":"27","author":"Bardai","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115867_bb0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","article-title":"Osteogenesis imperfecta and therapeutics","volume":"71\u201372","author":"Morello","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.bone.2021.115867_bb0030","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115867_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","article-title":"Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta","volume":"76","author":"Semler","year":"2011","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2021.115867_bb0040","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0045","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115867_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","article-title":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate","volume":"87","author":"Lindahl","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115867_bb0055","first-page":"36","article-title":"The role of prostaglandins in the regulation of bone metabolism","author":"Kawaguchi","year":"1995","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/15513819609168686","article-title":"Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms","volume":"16","author":"Faye-Petersen","year":"1996","journal-title":"Pediatr. Pathol. Lab. Med."},{"key":"10.1016\/j.bone.2021.115867_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1542\/peds.93.3.417","article-title":"Cortical hyperostosis: a complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation","volume":"93","author":"Woo","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2021.115867_bb0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","article-title":"Prostaglandins in bone: bad cop, good cop?","volume":"21","author":"Blackwell","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.115867_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1359\/jbmr.051110","article-title":"A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats","volume":"21","author":"Ke","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0080","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1073\/pnas.062053399","article-title":"Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation","volume":"99","author":"Yoshida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2021.115867_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41467-018-08097-7","article-title":"Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2021.115867_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lfs.2003.09.031","article-title":"EP2 and EP4 prostanoid receptor signaling","volume":"74","author":"Regan","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.bone.2021.115867_bb0095","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","article-title":"Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis","volume":"20","author":"Arns","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bone.2021.115867_bb0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2018.03.010","article-title":"Targeting therapeutics to bone by conjugation with bisphosphonates","volume":"40","author":"Young","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bone.2021.115867_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10237","article-title":"In vivo bone effects of a novel bisphosphonate-EP4a conjugate drug (C3) for reversing osteoporotic bone loss in an ovariectomized rat model","volume":"3","author":"Sheikh","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2021.115867_bb0110","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/jbm.b.34598","article-title":"Achieving enhanced bone regeneration using monetite granules with bone anabolic drug conjugates (C3 and C6) in rat mandibular defects","volume":"108","author":"Sheikh","year":"2020","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"10.1016\/j.bone.2021.115867_bb0115","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jbmr.2177","article-title":"First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome","volume":"29","author":"Chen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S8756-3282(01)00688-3","article-title":"Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro","volume":"30","author":"Tomita","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115867_bb0130","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.bjp.0703525","article-title":"Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor","volume":"130","author":"Davis","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2021.115867_bb0135","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115867_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115867_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbmr.3617","article-title":"Effect of anti-TGF-beta treatment in a mouse model of severe osteogenesis imperfecta","volume":"34","author":"Tauer","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115867_bb0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1203\/PDR.0b013e31815efd63","article-title":"High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment","volume":"63","author":"D\u2019Eufemia","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bone.2021.115867_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood.2019003480","article-title":"Epo receptor signaling in macrophages alters the splenic niche to promote erythroid differentiation","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bone.2021.115867_bb0175","article-title":"15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration","author":"Smith","year":"2020","journal-title":"bioRxiv"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:53:38Z","timestamp":1757613218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"alternative-id":["S8756328221000296"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115867","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115867"}}